 Nathan Gomes
Concepts (94)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Protein Synthesis Inhibitors | 2 | 2025 | 47 | 1.090 |
Why?
| | Hematologic Neoplasms | 1 | 2025 | 156 | 0.810 |
Why?
| | Protein Biosynthesis | 2 | 2025 | 433 | 0.800 |
Why?
| | High-Throughput Screening Assays | 1 | 2023 | 158 | 0.710 |
Why?
| | Gene Expression Regulation | 3 | 2010 | 2607 | 0.510 |
Why?
| | Positive Transcriptional Elongation Factor B | 3 | 2006 | 29 | 0.500 |
Why?
| | Tumor Suppressor Protein p53 | 3 | 2010 | 528 | 0.500 |
Why?
| | RNA Polymerase II | 4 | 2010 | 324 | 0.430 |
Why?
| | Antineoplastic Agents | 1 | 2025 | 2129 | 0.430 |
Why?
| | Chromosomal Proteins, Non-Histone | 2 | 2010 | 126 | 0.390 |
Why?
| | Apoptosis Regulatory Proteins | 2 | 2010 | 188 | 0.390 |
Why?
| | Promoter Regions, Genetic | 3 | 2010 | 1250 | 0.330 |
Why?
| | Repressor Proteins | 2 | 2010 | 427 | 0.320 |
Why?
| | Proto-Oncogene Proteins | 2 | 2010 | 648 | 0.320 |
Why?
| | Genes, p53 | 1 | 2010 | 72 | 0.320 |
Why?
| | Chromatin | 2 | 2010 | 519 | 0.320 |
Why?
| | Cell Cycle Proteins | 2 | 2010 | 617 | 0.310 |
Why?
| | Neoplasms | 1 | 2023 | 2671 | 0.280 |
Why?
| | Gene Products, tat | 2 | 2005 | 23 | 0.260 |
Why?
| | Peptides, Cyclic | 2 | 2020 | 259 | 0.250 |
Why?
| | Cell Line, Tumor | 4 | 2025 | 3412 | 0.230 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2025 | 872 | 0.220 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2025 | 139 | 0.220 |
Why?
| | Phosphorylation | 2 | 2025 | 1759 | 0.220 |
Why?
| | HIV Long Terminal Repeat | 1 | 2003 | 11 | 0.200 |
Why?
| | Apoptosis | 3 | 2025 | 2553 | 0.200 |
Why?
| | Biochemistry | 1 | 2003 | 38 | 0.200 |
Why?
| | Transcription, Genetic | 2 | 2006 | 1457 | 0.190 |
Why?
| | Drug Discovery | 1 | 2023 | 142 | 0.190 |
Why?
| | Protein Structure, Tertiary | 4 | 2010 | 861 | 0.180 |
Why?
| | CCCTC-Binding Factor | 2 | 2010 | 14 | 0.170 |
Why?
| | HIV-1 | 2 | 2005 | 864 | 0.170 |
Why?
| | HCT116 Cells | 2 | 2010 | 80 | 0.140 |
Why?
| | Chromatin Immunoprecipitation | 2 | 2010 | 138 | 0.140 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2010 | 121 | 0.140 |
Why?
| | Cell Proliferation | 1 | 2025 | 2475 | 0.140 |
Why?
| | Cell Line | 1 | 2023 | 2847 | 0.130 |
Why?
| | Radiation-Sensitizing Agents | 1 | 2015 | 43 | 0.120 |
Why?
| | Neoplastic Stem Cells | 1 | 2020 | 399 | 0.120 |
Why?
| | Kinetics | 2 | 2010 | 1670 | 0.110 |
Why?
| | Reproducibility of Results | 1 | 2023 | 3284 | 0.110 |
Why?
| | Head and Neck Neoplasms | 1 | 2020 | 606 | 0.110 |
Why?
| | Humans | 10 | 2025 | 137585 | 0.090 |
Why?
| | Nuclear Proteins | 2 | 2006 | 712 | 0.080 |
Why?
| | Transcription Factors, General | 1 | 2010 | 5 | 0.080 |
Why?
| | Peptide Elongation Factors | 1 | 2010 | 15 | 0.080 |
Why?
| | HeLa Cells | 3 | 2015 | 636 | 0.080 |
Why?
| | fas Receptor | 1 | 2010 | 95 | 0.080 |
Why?
| | CCAAT-Binding Factor | 1 | 2010 | 4 | 0.080 |
Why?
| | Mice | 2 | 2025 | 17787 | 0.080 |
Why?
| | RNA, Untranslated | 1 | 2010 | 124 | 0.080 |
Why?
| | Transcription Factors | 2 | 2006 | 1719 | 0.070 |
Why?
| | tat Gene Products, Human Immunodeficiency Virus | 2 | 2005 | 24 | 0.070 |
Why?
| | Protein Binding | 2 | 2010 | 2224 | 0.060 |
Why?
| | Transcription Factors, TFII | 1 | 2006 | 41 | 0.060 |
Why?
| | High Mobility Group Proteins | 1 | 2006 | 44 | 0.060 |
Why?
| | Transcription Factor TFIIH | 1 | 2006 | 37 | 0.060 |
Why?
| | Transcriptional Elongation Factors | 1 | 2006 | 40 | 0.060 |
Why?
| | Evolution, Molecular | 1 | 2010 | 493 | 0.060 |
Why?
| | Serine | 1 | 2006 | 141 | 0.060 |
Why?
| | Animals | 2 | 2025 | 36940 | 0.060 |
Why?
| | Histones | 1 | 2010 | 636 | 0.060 |
Why?
| | Protein Isoforms | 1 | 2006 | 404 | 0.060 |
Why?
| | Doxorubicin | 1 | 2006 | 362 | 0.050 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 976 | 0.050 |
Why?
| | Cyclin T | 1 | 2003 | 2 | 0.050 |
Why?
| | Chromatography | 1 | 2003 | 24 | 0.050 |
Why?
| | Glutathione Transferase | 1 | 2003 | 106 | 0.050 |
Why?
| | Cyclins | 1 | 2003 | 91 | 0.050 |
Why?
| | Flow Cytometry | 1 | 2006 | 1178 | 0.050 |
Why?
| | Transcriptional Activation | 1 | 2003 | 378 | 0.040 |
Why?
| | Peptide Chain Elongation, Translational | 1 | 2020 | 18 | 0.040 |
Why?
| | Blotting, Western | 1 | 2003 | 1226 | 0.040 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2020 | 141 | 0.040 |
Why?
| | Cell Nucleus | 1 | 2003 | 620 | 0.040 |
Why?
| | Recombinant Proteins | 1 | 2003 | 1353 | 0.040 |
Why?
| | Radiotherapy Dosage | 1 | 2020 | 268 | 0.040 |
Why?
| | DNA | 1 | 2006 | 1459 | 0.040 |
Why?
| | DNA-Binding Proteins | 1 | 2006 | 1502 | 0.040 |
Why?
| | Chemoradiotherapy | 1 | 2020 | 225 | 0.040 |
Why?
| | DNA Repair | 1 | 2020 | 231 | 0.040 |
Why?
| | DNA Damage | 1 | 2020 | 420 | 0.030 |
Why?
| | Cell Cycle | 1 | 2020 | 601 | 0.030 |
Why?
| | RNA | 1 | 2003 | 921 | 0.030 |
Why?
| | Models, Biological | 1 | 2003 | 1783 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2020 | 1079 | 0.030 |
Why?
| | Glioma | 1 | 2015 | 395 | 0.020 |
Why?
| | Brain Neoplasms | 1 | 2015 | 1238 | 0.020 |
Why?
| | Nuclear Receptor Coactivators | 1 | 2005 | 3 | 0.010 |
Why?
| | Ribonucleoprotein, U5 Small Nuclear | 1 | 2005 | 11 | 0.010 |
Why?
| | Open Reading Frames | 1 | 2005 | 123 | 0.010 |
Why?
| | Multiprotein Complexes | 1 | 2005 | 163 | 0.010 |
Why?
| | Alternative Splicing | 1 | 2005 | 229 | 0.010 |
Why?
| | Female | 1 | 2020 | 73304 | 0.010 |
Why?
|
|
Gomes's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|